JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/50/0.1/17.01.25

JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/50/0.1/17.01.25 Share Price

DE000JB6QGY7

Real-time Bid/Ask 02:30:18 02/07/2024 pm IST
0.075 ^EUR / 0.085 ^EUR	-13.04%

Current month	+12.20%
1 month	+31.43%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/50/0.1/17.01.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says	01/07	MT
Bristol Myers Squibb Named to Dow Jones Sustainability Index North America	01/07	AQ
Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	27/06	MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	27/06	MT

More news

Quotes 5-day view

Date	Price	Change
01/24/01	0.092	+12.20%
28/24/28	0.082	-11.83%
27/24/27	0.093	-6.06%
26/24/26	0.099	+5.32%
25/24/25	0.094	-6.00%

Delayed Quote Börse Stuttgart

Last update July 01, 2024 at 12:01 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	J.P. Morgan
WKN	JB6QGY
ISIN	DE000JB6QGY7
Date issued	15/11/2023
Strike	50 $
Maturity	17/01/2025 (200 Days)
Parity	10 : 1
Emission price	0.56 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.68 €
Lowest since issue	0.069 €
Delta	0.19x
Omega	9.259
Premium	23.14x
Gearing	48.17x
Moneyness	0.8260
Difference Strike	8.7 $
Difference Strike %	+17.40%
Spread	0.01 €
Spread %	11.76%
Theoretical value	0.0800
Implied Volatility	28.89 %
Total Loss Probability	85.72 %
Intrinsic value	0.000000
Present value	0.0800
Break even	50.86 €
Theta	-0x
Vega	0.01x
Rho	0x

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.3 USD

Average target price

53.19 USD

Spread / Average Target

+28.80%

Consensus